Meet with... Astellas Venture Management
CIC Cambridge , Havana Room , Cambridge , MA 02142
October 13, 2015 from 12:30 PM to 14:30 PM (EST)
$10 - $35
Investing in opportunities to improve health through innovation is a key driver of solutions for today’s most difficult healthcare problems. Astellas Venture Management (AVM) /Innovation Management (“AIM”) are interested in supporting early stage opportunities to advance the creation of human therapeutics. AVM/AIM will be presenting at Johnson and Johnson Innovation, JLABS on October 13th, 2015.
AVM is the venture group within Japan's one of largest pharmaceutical company, Astellas Pharma Inc. You may be familiar with some of AVM’s successful, local portfolio companies including Potenza Therapeutics, Raze Therapeutics, Verastem and Epizyme. With hundreds of millions in an evergreen fund, AVM is looking to invest in more private companies in the early stage drug discovery and platform technology across several therapeutic areas, including:
- Immunology and Inflammation, Urology, Oncology, Nephrology and Neuroscience
- Ophthalmology, Hearing Loss, Muscle disorder and Regenerative Medicine.
Also, AVM has another mission by AIM to execute early stage innovative collaborations with Academia and biotech companies. Recent collaboration deals include Mitobridge (Mitochondria diseases, drug discovery), Harvard Medical School (Retinitis Pigmentosa, Target identification), Proteostasis (Diseases caused by defects in protein folding, Drug discovery), DFCI (Oncology, drug discovery), Potenza (Immune oncology, drug discovery) and Kanyos Therapeutics (Autoimmune, drug discovery). AVM/AIM will provide equity and non-dilutive capitals to our portfolios and partners while actively looking for the new innovative opportunities.
Representatives from AVM/AIM will be in attendance to give an overview presentation on the company's key areas of interest and best practices when seeking funding. Following the presentation, don't miss this opportunity to network with fellow attendees and the AVM/AIM representatives during lunch. For those companies who apply online and receive approval, one-on-one meetings with AVM will provide a private forum to discuss your company.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on September 15th.
AVM Participating Representatives:
Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management read bio»
Takashi Futami | Associate Investment Director, Astellas Venture Management read bio»
Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management read bio»
Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Management read bio»
Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Management read bio»
About Astellas Venture Management LLC:
Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to helping Astellas Pharma Inc. to achieve its strategic goals. The venture capital activity of AVM can be traced back to the year 1999. Through its strategic investments in private early-stage companies, the funds aim to forge relationships with Astellas Pharma, which may lead to larger collaborations in the future. AVM is able to provide portfolio companies with invaluable advice and assistance. Astellas Pharma Inc., the ultimate parent company of AVM, headquartered in Tokyo, was created on April 1, 2005 through the merger of two Japanese pharmaceutical companies. Astellas is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products." With this philosophy, Astellas focuses on highly specialized therapeutic areas (categories) where there is a high degree of unmet medical needs.
About Innovation Management:
Innovation Management ("AIM") is a newly established organization at Astellas Headquarter. AIM is a dedicated function for external collaboration to promote intake early stage innovation into Astellas R&D. AIM has closed several deals since its inception (Oct, 2013) including Mitokyne (mitochondrial disease drug discovery), Cancer Research UK (oncology target discovery), Harvard Medical School (ophthalmology target discovery), Dana-Farber Cancer Institute (oncology drug discovery) and Proteostasis (genetic disease drug discovery).
About Astellas Pharma Inc.:
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney Diseases.
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until October 12th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on September 15th. Your application will be reviewed and you will be notified of acceptance on September 29th, 2015. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
AVM participating Representatives' biographies:
Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management
Mr. Sakae Asanuma joined AVM in June 2011. Prior to joining AVM, he served as Director at Yasuda Enterprise Development America, Japan's major VC firm with $800M under management, from 2000 to 2011 and originated Yasuda's biotech investment activities in the US. Based in Bay Area since 2000, he has invested in 30+ US biotech venture companies and deeply involved in the business development discussions with Japanese pharmaceutical companies on behalf of his portfolios. To date, his portfolio companies successfully achieved 9 IPOs and 8 M&As. Prior to Yasuda, he was venture capitalist and buy-side equity analyst from 1988 to 1999, managing $20B+ equity portfolios for Meiji-Yasuda Life Insurance Company (one of the largest life insurance companies in Japan). He holds Master of Business Administration from Carnegie Mellon University.
Connect with Sakae:
Takashi Futami | Associate Investment Director, Astellas Venture Management
Mr. Futami joined Astellas Venture Management in Oct 2013. Prior to joining AVM, he worked as a Senior Researcher at Astellas Pharma Inc. He served as a team leader at Oncology Labs of Astellas Pharma, and led a drug discovery research and preclinical development of kinase inhibitor programs in oncology therapeutics area. He also has experiences of collaboration with several institution like The University of Tokyo Hospital, Metabolex Inc. etc.
Connect with Takashi:
Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management
Dr. Masunaga joined Astellas Venture Management in Oct 2013. He has more than 25 years experience of drug discovery research from target discovery to development mainly in Immunology area including transplantation and autoimmune. From 2007 to 2012, he served as associate director to start up the Astellas Research Institute of America (ARIA) which is engaging early drug discovery (target identification, Hit/Lead generation and therapeutic strategy) in transplantation. Prior to joining AVM, he worked as a head of Advanced Drug Discovery (ADD) group in Pharmacology Research Laboratories taking a responsibility for early drug discovery of small molecules for every single focused therapeutic area, Urology, Oncology, Immunology, CNS, Kidney diseases and Frontier diseases.
Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Management
Dr. Matsuoka joined AVM in October 2014. He has more than 14 years experiences of drug discovery research in the field of immunology, cell biology, and molecular biology at Astellas Pharma Inc., and served as a principal scientist at Astellas Research Institute of America (ARIA) from 2007 to 2010 specifically focusing on early drug discovery (target identification, Hit/Lead generation and therapeutic strategy development) in transplantation. Prior to joining AVM, he served as a senior manager in charge of scientific evaluation at Astellas Innovation Management (AIM) and has a significant track record of leading several partnering deals.
Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Management
Dr. Shindoh joined AVM in November 2014. He has 18 years experiences of drug discovery research in the field of Oncology, Urology and renal disease at Astellas Pharma Inc. and covers broad range of drug discovery from target identification to clinical development with successful experience in oncology. From 2011-2012, he worked at the Dana-Farber Cancer Institute as a visiting scientist to identify novel drug targets. Since Oct 2013, he served as associate director of Astellas Innovation Management (AIM) in charge of scientific evaluation in the oncology disease area and led the partnering with CRUK.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.